대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Impact of Tocotrienol Supplementation on Renal Functions and Lipid Profiles in Patients With Kidney Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
저자	Omar Elkoumi
출판정보	2025; 2025(1):
키워드	Tocotrienols, Kidney diseases, eGFR
초록	Kidney diseases, including glomerular, tubulointerstitial, and vascular disorders, as well as dialysis dependence, are linked to oxidative stress, inflammation, and dyslipidemia. Tocotrienols, vitamin E isomers, have been proposed as a potential therapeutic intervention, yet their clinical efficacy remains uncertain. This systematic review and meta-analysis evaluate the effects of tocotrienol supplementation on renal function and lipid profiles in patients with kidney diseases. A systematic search of PubMed, Scopus, Web of Science, and Cochrane CENTRAL was conducted from inception to February 27, 2025. Randomized controlled trials (RCTs) assessing tocotrienol supplementation in kidney disease patients compared to placebo were included. Meta-analysis was performed using a fixed-effects model, with pooled standardized mean differences (SMDs) and mean differences (MDs) with 95% confidence intervals (CIs). Four RCTs with 224 participants met the inclusion criteria. Tocotrienol supplementation significantly improved eGFR (MD = 4.13, 95% CI: 0.56 to 7.69, p = 0.02) and reduced serum creatinine levels (SMD = -0.42, 95% CI: -0.77 to -0.07, p = 0.02), both with low heterogeneity (I² = 0%). However, the reduction in urea was not statistically significant (SMD = -0.28, 95% CI: -0.63 to 0.07, p = 0.11). Tocotrienols significantly increased HDL (SMD = 0.64, 95% CI: 0.25 to 1.03, p = 0.001) and reduced LDL (SMD = -0.49, 95% CI: -0.87 to -0.11, p = 0.01). Triglyceride reduction was borderline significant (SMD = -0.38, 95% CI: -0.75 to 0.00, p = 0.05), while total cholesterol remained unchanged (SMD = -0.09, 95% CI: -0.47 to 0.28, p = 0.62). Tocotrienol supplementation demonstrates renoprotective effects by improving eGFR and reducing serum creatinine levels in kidney disease patients. It also enhances lipid profiles by increasing HDL and lowering LDL. However, its effects on total cholesterol and triglycerides warrant further investigation in larger RCTs with longer follow-ups.
원문(PDF)	PDF 원문보기

목록

위로가기